Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Davis R M Inc.

Davis R M Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,893 shares of the medical research company's stock after acquiring an additional 4,225 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.6% of Davis R M Inc.'s investment portfolio, making the stock its 16th largest holding. Davis R M Inc.'s holdings in Thermo Fisher Scientific were worth $81,585,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Signature Resources Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after acquiring an additional 35 shares during the period. Peterson Financial Group Inc. purchased a new position in Thermo Fisher Scientific during the third quarter valued at approximately $27,000. New Millennium Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $29,000. Stephens Consulting LLC grew its position in Thermo Fisher Scientific by 116.0% during the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after buying an additional 29 shares during the period. Finally, Bank & Trust Co purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $33,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Bank of America boosted their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. Bernstein Bank boosted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research report on Tuesday, October 22nd. Finally, Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Thermo Fisher Scientific Trading Up 0.0 %

Shares of TMO stock traded up $0.23 on Monday, hitting $513.49. The stock had a trading volume of 1,377,571 shares, compared to its average volume of 1,494,738. The company's 50 day moving average price is $575.70 and its 200-day moving average price is $580.20. Thermo Fisher Scientific Inc. has a 1 year low of $480.57 and a 1 year high of $627.88. The firm has a market capitalization of $196.41 billion, a P/E ratio of 32.18, a P/E/G ratio of 3.39 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. During the same period last year, the firm earned $5.69 earnings per share. The company's revenue for the quarter was up .2% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.30%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company's stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.